Q1 EPS Forecast for Edwards Lifesciences Lowered by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Research analysts at Zacks Research cut their Q1 2025 earnings estimates for shares of Edwards Lifesciences in a note issued to investors on Thursday, November 14th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $0.59 for the quarter, down from their prior estimate of $0.69. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.62 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.70 EPS and Q3 2026 earnings at $0.71 EPS.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the company posted $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis.

Other analysts have also issued reports about the stock. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Barclays reduced their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Piper Sandler reduced their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. UBS Group reduced their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Finally, Wells Fargo & Company reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $67.76 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market capitalization of $39.96 billion, a P/E ratio of 9.78, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. The company’s 50-day moving average is $67.44 and its 200 day moving average is $76.12.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock worth $2,744,438 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently made changes to their positions in EW. Avantax Advisory Services Inc. grew its position in Edwards Lifesciences by 4.1% during the 1st quarter. Avantax Advisory Services Inc. now owns 6,887 shares of the medical research company’s stock worth $658,000 after purchasing an additional 272 shares during the period. M&G Plc acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $853,000. O Shaughnessy Asset Management LLC boosted its position in Edwards Lifesciences by 27.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 36,897 shares of the medical research company’s stock worth $3,526,000 after purchasing an additional 7,918 shares in the last quarter. Seven Eight Capital LP boosted its position in Edwards Lifesciences by 2.6% in the 1st quarter. Seven Eight Capital LP now owns 17,613 shares of the medical research company’s stock worth $1,683,000 after purchasing an additional 441 shares in the last quarter. Finally, Lake Street Advisors Group LLC grew its stake in shares of Edwards Lifesciences by 36.2% during the 1st quarter. Lake Street Advisors Group LLC now owns 3,573 shares of the medical research company’s stock worth $341,000 after purchasing an additional 950 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.